Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615351 | 0.90 | GSTO1 (0.47) | ALDH1A1MAPTGSTO1KDM4EPOLB | |
| SCHEMBL3604447 | 0.84 | GSTO1 (0.42) | ALDH1A1MAPTGSTO1KDM4EPOLB | |
| SCHEMBL3600139 | 0.79 | GSTO1 (0.52) | MAPTGSTO1KDM4EPOLBMEN1 | |
| SCHEMBL3610003 | 0.79 | GSTO1 (0.53) | MAPTGSTO1POLBMEN1KMT2A | |
| SCHEMBL3614294 | 0.78 | GSTO1 (0.50) | ALDH1A1MAPTGSTO1POLBMEN1 | |
| SCHEMBL3602399 | 0.75 | GSTO1 (0.50) | MAPTGSTO1POLBLMNATP53 | |
| SCHEMBL5599981 | 0.75 | HSD11B1 (0.46) | ALDH1A1MAPTHPGDHSD11B1MEN1 | |
| SCHEMBL3607138 | 0.75 | SIGMAR1 (0.65) | — | |
| SCHEMBL3601049 | 0.73 | GSTO1 (0.48) | ALDH1A1MAPTGSTO1POLBLMNA | |
| SCHEMBL3609508 | 0.72 | GSTO1 (0.47) | ALDH1A1MAPTGSTO1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| EP-2176229-B1 | NOVEL CRYSTALLINE FORM OF 3-(DIFLUORMETHYL)-1-METHYL-N -(3',4',5'-TRIFLUOR[1,1'-BIPHENYL]-2-YL)-1H-PYRAZOL-4-CARBOXAMIDE | BASF SE (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20100160311-A1 | Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them | BASF SE (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| EP-2176229-A1 | NOVEL CRYSTALLINE FORM OF 3-(DIFLUORMETHYL)-1-METHYL-N -(3',4',5'-TRIFLUOR[1,1'-BIPHENYL]-2-YL)-1H-PYRAZOL-4-CARBOXAMIDE | BASF SE (DE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2057150-A1 | THIOPHENE-SULFONIC ACID PICOLYL AMIDES | BASF SE (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009007344-A1 | NOVEL CRYSTALLINE FORM OF 3-(DIFLUORMETHYL)-1-METHYL-N -(3',4',5'-TRIFLUOR[1,1'-BIPHENYL]-2-YL)-1H-PYRAZOL-4-CARBOXAMIDE | BASF SE (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008107398-A2 | PYRAZINE COMPOUNDS | BASF SE (DE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008022937-A1 | THIOPHENE-SULFONIC ACID PICOLYL AMIDES | BASF SE (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160311-A1 | Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them | G6PD, CYP51A1, ERG28 | ALDH1A1 912/4885MAPT 1401/4885HPGD 1757/4885 |
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | ALDH1A1 370/4885MAPT 2986/4885HPGD 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.